Basic Information
| LncRNA/CircRNA Name | FOXD2-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:47432133-47434641 |
| Ensemble | ENSG00000237424 |
| Refseq | NR_026878 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | temozolomide | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | Western blot analysis, PCR |
| Sample | glioma cell lines U251 and A172 |
| Expression Pattern | up-regulated |
| Function Description | FoxD2-AS1 was overexpressed in recurrent glioma, high FoxD2-AS1 expression was significantly correlated with poor patient outcome. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) is significantly less frequent in high FoxD2-AS1 expression patients. Knockdown of FoxD2-AS1 decreased the proliferation, metastatic ability of glioma cells and promote the sensitivity to TMZ in glioma cells. Furthermore, knockdown of FoxD2-AS1 induced hypermethylation of the promoter region of MGMT. |
| Pubmed ID | 31680769 |
| Year | 2019 |
| Title | FoxD2-AS1 Is a Prognostic Factor in Glioma and Promotes Temozolomide Resistance in a O 6-methylguanine-DNA Methyltransferase-Dependent Manner |
External Links
| Links for FOXD2-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |